Should I buy or sell Affimed stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares. View AFMD analyst ratings or view top-rated stocks .

What is Affimed's stock price target for 2024?

8 Wall Street research analysts have issued 1 year price objectives for Affimed's shares. Their AFMD share price targets range from $1.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,110.4% from the stock's current price. View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts .

How have AFMD shares performed in 2023?

Affimed's stock was trading at $1.24 on January 1st, 2023. Since then, AFMD shares have decreased by 63.4% and is now trading at $0.4544. View the best growth stocks for 2023 here .

Are investors shorting Affimed?

Affimed saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,640,000 shares, a drop of 24.1% from the October 31st total of 2,160,000 shares. Based on an average trading volume of 562,700 shares, the days-to-cover ratio is presently 2.9 days. View Affimed's Short Interest .

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AFMD earnings forecast .

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 104.40% and a negative net margin of 638.68%. During the same quarter in the prior year, the firm earned ($0.08) EPS.

What other stocks do shareholders of Affimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX) , JetBlue Airways (JBLU) , SentinelOne (S) , American International Group (AIG) , Sorrento Therapeutics (SRNE) , Catalyst Pharmaceuticals (CPRX) , Amarin (AMRN) , Rigel Pharmaceuticals (RIGL) , Viking Therapeutics (VKTX) and Lipocine (LPCN) .

Who are Affimed's major shareholders?

Affimed's stock is owned by many different retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (5.51%), Acadian Asset Management LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Affimed Stock Price, News & Analysis (NASDAQ:AFMD)

$0.45

0.00 (0.00%)

(As of 12/4/2023 ET)

Compare

Today's Range: $0.44
▼
$0.47
50-Day Range: $0.32
▼
$0.52
52-Week Range: $0.22
▼
$2.15

Volume: 373,125 shs
Average Volume: 888,023 shs
Market Capitalization: $67.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Affimed MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 1,110.4% Upside
$5.50 Price Target
Short Interest: Healthy
1.10% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: 0.93
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.81) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

173rd out of 952 stocks

Pharmaceutical Preparations Industry

70th out of 434 stocks

3.4

Analyst's Opinion

Consensus Rating
Affimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Affimed has a forecasted upside of 1,110.4% from its current price of $0.45.
Amount of Analyst Coverage
Affimed has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.10% of the outstanding shares of Affimed have been sold short.
Short Interest Ratio / Days to Cover
Affimed has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Affimed has recently decreased by 24.07%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Affimed does not currently pay a dividend.
Dividend Growth
Affimed does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Affimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.
Environmental Sustainability
The Environmental Impact score for Affimed is -1.95.

3.3

News and Social Media Coverage

News Sentiment
Affimed has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Affimed this week, compared to 1 article on an average week.
Search Interest
10 people have searched for AFMD on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Affimed insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.80% of the stock of Affimed is held by insiders.
Percentage Held by Institutions
Only 30.82% of the stock of Affimed is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Affimed are expected to grow in the coming year, from ($0.81) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Affimed is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Affimed is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Affimed has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Affimed Stock (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AFMD Stock News Headlines

December 4, 2023 | finance.yahoo.com

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

December 1, 2023 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Short Interest Update

December 5, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

November 30, 2023 | msn.com

Affimed slips as finance chief and science chief depart

November 29, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Affimed (NASDAQ:AFMD)

November 20, 2023 | markets.businessinsider.com

Promising Investment Potential in Affimed’s Stock: Harnessing Clinical Trials for Lymphoma Treatment and FDA Meeting Resolution

November 20, 2023 | finance.yahoo.com

Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript

November 17, 2023 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on Affimed (AFMD)

December 5, 2023 | Edge On The Street (Ad)

The Battery Metal Nobody Told You About

According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."

November 15, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Syros Pharmaceuticals (SYRS), Affimed (AFMD)

November 14, 2023 | finance.yahoo.com

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

November 14, 2023 | benzinga.com

Recap: Affimed Q3 Earnings

November 9, 2023 | finance.yahoo.com

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

November 7, 2023 | finance.yahoo.com

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

November 7, 2023 | morningstar.com

Affimed NV AFMD

November 3, 2023 | finance.yahoo.com

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

November 1, 2023 | finance.yahoo.com

Affimed to Participate in Upcoming Investor Conferences

October 25, 2023 | finance.yahoo.com

Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround

October 4, 2023 | finanznachrichten.de

Affimed N.V.: Affimed Announces Listing Transfer to Nasdaq Capital Markets

October 4, 2023 | finance.yahoo.com

Affimed Announces Listing Transfer to Nasdaq Capital Markets

September 27, 2023 | finance.yahoo.com

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

September 25, 2023 | benzinga.com

What 6 Analyst Ratings Have To Say About Affimed

September 21, 2023 | finance.yahoo.com

Affimed to Present at the Cantor Global Healthcare Conference 2023

September 12, 2023 | markets.businessinsider.com

Affimed Says FDA Grants Fast Track Designation For AFM13 With AlloNK To Treat R/r Hodgkin Lymphoma

September 7, 2023 | msn.com

Cantor Fitzgerald Reiterates Affimed N.V. (AFMD) Overweight Recommendation

September 7, 2023 | markets.businessinsider.com

Expert Ratings for Affimed

August 23, 2023 | finance.yahoo.com

Is Affimed NV Set to Underperform? Analyzing the Factors Limiting Growth

See More Headlines

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AFMD
CUSIP: N/A
CIK: 1608390
Web: www.affimed.com
Phone: 496221674360
Fax: 49-6221-653-0777
Employees: 219
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $7.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +1,110.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-90,610,000.00
Net Margins: -638.68%
Pretax Margin: -641.56%
Return on Equity: -104.40%
Return on Assets: -75.85%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 3.70
Quick Ratio: 3.67

Sales & Book Value

Annual Sales: $43.58 million
Price / Sales: 1.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.31 per share
Price / Book: 0.35

Miscellaneous

Outstanding Shares: 149,340,000
Free Float: 143,664,000
Market Cap: $67.86 million
Optionable: Optionable
Beta: 2.05

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Adi Hoess M.D. (Age 62)
Ph.D., CEO, MD & Member of Management Board
Comp: $818.55k
Mr. Angus W. Smith (Age 41)
CFO & Member of Management Board
Comp: $673.91k
Dr. Wolfgang Fischer (Age 59)
MD, COO & Member of Management Board
Comp: $638.55k
Ms. Denise Mueller (Age 53)
Chief Business Officer & Member of Management Board
Comp: $621.41k
Dr. Andreas Harstrick M.D. (Age 62)
Chief Medical Officer & Member of Management Board
Comp: $529.27k
Dr. Arndt Justus Georg Schottelius M.D. (Age 57)
Ph.D., Chief Scientific Officer & Member of Management Board
Comp: $641.77k
Prof. Melvyn Little
Founder & Consultant
Mr. Michael Wolf (Age 56)
Head of Finance & Administration
Mr. Alexander Fudukidis
Head of Investor Relations & Director of Investor Relations
Mary Beth Sandin
Vice President of Marketing & Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AFMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Affimed stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.
What is Affimed's stock price target for 2024?: 8 Wall Street research analysts have issued 1 year price objectives for Affimed's shares. Their AFMD share price targets range from $1.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,110.4% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.
How have AFMD shares performed in 2023?: Affimed's stock was trading at $1.24 on January 1st, 2023. Since then, AFMD shares have decreased by 63.4% and is now trading at $0.4544.
View the best growth stocks for 2023 here.
Are investors shorting Affimed?: Affimed saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,640,000 shares, a drop of 24.1% from the October 31st total of 2,160,000 shares. Based on an average trading volume of 562,700 shares, the days-to-cover ratio is presently 2.9 days.
View Affimed's Short Interest.
When is Affimed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AFMD earnings forecast.

How were Affimed's earnings last quarter?: Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 104.40% and a negative net margin of 638.68%. During the same quarter in the prior year, the firm earned ($0.08) EPS.
What other stocks do shareholders of Affimed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).
Who are Affimed's major shareholders?: Affimed's stock is owned by many different retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (5.51%), Acadian Asset Management LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Affimed?: Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AFMD) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial